Antibodies against programmed cell death protein 1 (PD1) or programmed death-ligand 1 (PD-L1) are immune checkpoint inhibitors (ICIs) that exert their anti-tumor effects by reinvigorating T cells in the tumor microenvironment (TME) [1]. This evidence concerns the gene CD274 and neoplasm.